Email us for help
Dr. Paul Richardson of the Dana Farber Cancer Institute shares a mid-year myeloma review of ASCO, EHA and upcoming International Myeloma Society findings of the fast-moving research being performed in myeloma. Updates will include the expanding world of bispecific antibodies that include one FDA-approved drug and anticipated approvals for two new bispecific antibodies. He will also discuss exciting results from CAR T cinical trials, CAR T newcomers, sequencing preferences, BCMA targeted therapies, new therapy targets in myeloma, MRD advances, blood-based testing, clinical trials end points and more.
Thanks to our episode sponsor, Karyopharm.